The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer

Neoplasms, Therapy-Associated Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02523495
• Other study ID #: TJCC003-TTMCRC
• Status: Recruiting
• Start date: June 2012
• Est. completion date: July 2022

Study information

• Verified date: August 2018
• Source: Huazhong University of Science and Technology
• Contact: Yuan Xianglin, Professional
• Phone: 13667241722
• Email: yxl[@]medmail.com.cn
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Through clinical observation and data statistics, conclude the clinical outcome of target therapy in metastasis colorectal cancer and explore some biomarkers that relate to target therapy.

Description:

1. Establish a clinical database of patients who are diagnosed with metastasis colorectal cancer in tongji hospital.

2. Build a biological specimen banks of metastasis colorectal cancer through collecting blood samples from those patients who have reached an agreement with us.

3. Through clinical observation and data statistics, conclude the clinical outcome of target therapy in metastasis colorectal cancer.

4. To extract DNA from the blood and explore some biomarkers that related to target therapy in metastasis colorectal cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: July 2022
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Metastasis colorectal cancer confirmed by histologically and radiography

2. Receive target therapy over half a year

3. Have a measurable lesions

Exclusion Criteria:

1. A history of other malignant tumors in five years

Related Conditions & MeSH terms

• Neoplasms, Second Primary
• Neoplasms, Therapy-Associated

Locations

Country	Name	City	State
China	Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Huazhong University of Science and Technology

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival		5 years